<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="161424">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01882595</url>
  </required_header>
  <id_info>
    <org_study_id>Nebu Tracheo</org_study_id>
    <nct_id>NCT01882595</nct_id>
  </id_info>
  <brief_title>Influence of Tracheostomy on Lung Deposition in Spontaneously Breathing Patient</brief_title>
  <official_title>Influence of Tracheostomy on Lung Deposition in Spontaneously Breathing Patient</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <authority>Belgium: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare lung deposition of amikacin in two settings: spontaneously breathing through a
      tracheostomy cannula and through the mouth.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Amikacin urinary drug concentration</measure>
    <time_frame>At each micturition during 24 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Tracheostomized Patients</condition>
  <arm_group>
    <arm_group_label>Nebulization through the tracheostomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subjects received two nebulization sessions. The first session was performed prior the tracheostomy removal (through the tracheostomy) and the second one when the when the tracheostome was totally scared (through the mouth)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nebulization through the mouth</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subjects received two nebulization sessions. The first session was performed prior the tracheostomy removal (through the tracheostomy) and the second one when the when the tracheostome was totally scared (through the mouth)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Nebulization through the tracheostomy</intervention_name>
    <description>Each subject received two nebulization sessions under spontaneous breathing in a sitting position. The first session was performed prior to tracheostomy removal. During the first nebulization, subjects inhaled the aerosol through the tracheostomy, cuff inflated and inner cannula removed.</description>
    <arm_group_label>Nebulization through the tracheostomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Nebulization through the mouth</intervention_name>
    <description>Each subject received two nebulization sessions under spontaneous breathing in a sitting position. The second nebulization was performed when the tracheostome was totally scarred. During the second nebulization, subjects inhaled the aerosol a mouth piece and wore a nose clip.</description>
    <arm_group_label>Nebulization through the mouth</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient who were likely to require an elective tracheostomy surgery as part as their
             head and neck surgery

        Exclusion Criteria:

          -  Allergy to Aminoglycosides

          -  Patients who received Aminoglycosides treatment less than one month prior the surgery

          -  Pectoralis major flap reconstruction

          -  Latissimus dorsi flap reconstruction
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 18, 2013</lastchanged_date>
  <firstreceived_date>June 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</investigator_affiliation>
    <investigator_full_name>laurentpitance</investigator_full_name>
    <investigator_title>Doctor in physiotherapy</investigator_title>
  </responsible_party>
  <keyword>Nebulization aerosol nebulizer tracheostomy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
